

---

**FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY**

---

December 1, 2004

TO: Examiner Maryam Monshipouri  
Group 1652  
571-272-0932

RECEIVED  
CENTRAL FAX CENTER  
DEC 01 2004

FROM Justin D. Karjala  
Celera Genomics Corp.  
(240) 453-3812

FAX NO: (703) 872-9306

# OF PAGES (incl. cover): 6

---

Re: U.S. Serial No. 10/760,407, filed January 21, 2004  
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID  
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES  
THEREOF"  
Atty. Docket No.: CL001306-DIVII

A Preliminary Amendment (Restriction Election) in the above-identified application follows. No fee is due for this submission.

---

*The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Chunhua YAN et al.

Art Unit: 1652

Serial No.: 10/760,407

Examiner: M. Monshipouri

Filed: January 21, 2004

Atty. Docket: CL001306-DIVII

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

RECEIVED  
CENTRAL FAX CENTER  
DEC 01 2004

**PRELIMINARY AMENDMENT**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

*By Facsimile*

Sir:

This is in response to an Office Action mailed on November 1, 2004 from Examiner Monshipouri in which a restriction requirement was issued for the above-referenced application.

By way of response, Applicants hereby elect claim group II, claim 3, directed to antibodies, etc., for examination and have canceled claims corresponding to the non-elected groups I, III-IV, and VI-VIII.

However, Applicants respectfully request that claim 12 be included with group II. The Examiner included claim 12 in group V, and described group V as drawn to methods of detecting nucleic acids utilizing kinase-encoding nucleic acids as probes in a hybridization assay. This is not accurate with respect to claim 12, which is not drawn to using nucleic acids as probes in a hybridization assay. Rather, claim 12 is drawn to methods of detecting peptides using a detection agent such as an antibody. Accordingly, Applicants are hereby amending claim 12 and presenting new claims 24-30 drawn to methods of detecting a polypeptide, such as by using an antibody, and respectfully request examination of these claims.

Please amend the application as follows: